EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes
Open Label Trial to Evaluate the Tolerability of a Combination Therapy Consisting of GAD-alum (Diamyd®), Etanercept and Vitamin D in Children and Adolescents Newly Diagnosed With Type 1 Diabetes
The objectives of this study is to:
- Evaluate the tolerability of a combination therapy with Diamyd, vitamin D and etanercept
- Evaluate how the above mentioned treatments influence the immune system and endogenous insulin secretion
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Helsingborg, Sweden
- Helsingborg Hospital
-
Linköping, Sweden
- Linköping University Hospital
-
Lund, Sweden
- Lund University Hospital
-
Malmö, Sweden
- Skåne University Hospital, UMAS
-
Stockholm, Sweden
- Sachsska, Södersjukhuset
-
Uddevalla, Sweden
- Uddevalla Hospital
-
Västerås, Sweden
- Västerås Hospital
-
Örebro, Sweden
- Örebro University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed consent given by patients and parent(s)/legal guardian(s)
- Type 1 diabetes according to the ADA classification, diagnosed within the previous 100 days at the time of screening
- Age 8.00 -17.99 years at time of screening
- Fasting C-peptide at time of screening ≥0.12 nmol/L
- Positive for GADA but < 50 000 Units
- Menarchal females must agree to avoid pregnancy and have a negative urine pregnancy test
- Immunity against Varicella, either through previous infection or vaccination
- Patients must follow the Swedish vaccination programme
- Patients of childbearing potential must agree to using adequate contraception, if sexually active, until 1 year after the last administration of GAD-alum and etanercept. Adequate contraception is as follows:
For females of childbearing potential:
- oral (except low-dose gestagen (lynestrenol and norethisterone), injectable, or implanted hormonal contraceptives (females)
- intrauterine device (females)
- intrauterine system (for example, progestin-releasing coil) (females)
- vasectomized male (with appropriate postvasectomy documentation of the absence of sperm in the ejaculate)
For males of childbearing potential:
a. Condom (male)
Exclusion Criteria:
- Previous or current treatment with immunosuppressant therapy (although topical or inhaled steroids are accepted)
- Continuous treatment with anti-inflammatory drug (sporadic treatment e.g. because of headache or in connection with fever a few days will be accepted)
- Treatment with any oral or injected anti-diabetic medications (especially hypoglycemic agents) other than insulin
- Treatment with Vitamin D, marketed or not, or unwilling to abstain from such medication during the trial
- A history of hypercalcemia
- A history of anaemia or significantly abnormal haematology results at screening
- A history of epilepsy, head trauma or cerebro-vascular accident, or clinical features of continuous motor unit activity in proximal muscles
- Clinically significant history of acute reaction to vaccines or other drugs in the past
- Treatment with any vaccine within 4 months prior to planned first administration of GAD-Alum or planned treatment with vaccine up to 4 months after the last injection with GAD-Alum, including influenza vaccine
- Participation in other clinical trials with a new chemical entity within the previous 3 months
- Inability or unwillingness to comply with the provisions of this protocol
- A history of alcohol or drug abuse
- A significant illness other than diabetes within 2 weeks prior to first dosing
- Known human immunodeficiency virus (HIV)
- Prior or active viral hepatitis B or C infection
- Females who are lactating or pregnant (for females who have started menstruating the possibility of pregnancy must be excluded by urine βHCG on-site within 24 hours prior to the GAD-Alum and etanercept administration, respectively)
- Males or females not willing to use adequate contraception, if sexually active, until 1 year after the last GAD-Alum and etanercept administration, respectively
- Presence of associated serious disease or condition, including active skin infections that preclude subcutaneous injection, which in the opinion of the investigator makes the patient non-eligible for the study.
- Deemed by the investigator not being able to follow instructions and/or follow the study protocol
- Active infection, including chronic and local infection or a history of previous tendency to serious infections, recent or ongoing uncontrolled bacterial, viral, fungal or other opportunistic infections, or known infection with active EBV or CMV
- Hypersensitivity to the active substance in Enbrel (etanercept) or other ingredients in Enbrel
- Active or inactive (latent) tuberculosis (TBC) at screening
- History of malignancy or significant cardiovascular disease
- Current or history of leukopenia, anemia and/or thrombocytopenia
- Liver disease (clinical or hepatic enzymes >3 times the upper limit of normal (ULN))
- Renal insufficiency (clinical or creatinine >3 times the upper limit of normal (ULN))
- MS, undefined neurologic condition or known SLE, or anti-nuclear or known doublestranded DNA antibody positivity
- Arrhythmia
- Pancreatitis
- Vitamin D serum levels >100 nmol/L at screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: A
All patients will from Day 1 receive 2 000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
|
Other Names:
Recombinant Human Glutamic Acid Decarboxylase (rhGAD65)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Patients With Reactions of the Injection Site as an Assessment of the Tolerability
Time Frame: 1 months
|
Number of patients with reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching, Other).
Inspection of injection site 60 minutes after GAD-Alum injection by investigator or nurse
|
1 months
|
|
Number of Patients With Reactions of the Injection Site as an Assessment of the Tolerability
Time Frame: 2 months
|
Number of patients with reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching, Other).
Inspection of injection site 60 minutes after GAD-Alum injection by investigator or nurse
|
2 months
|
|
Number of Patients With Any Abnormal Findings From Physical Examinations After Baseline
Time Frame: Month 1, 2, 3, 6, 9, 15 and 30
|
Number of patients with any abnormal findings from physical examinations after baseline, including neurological assessments as an assessment of tolerability.
|
Month 1, 2, 3, 6, 9, 15 and 30
|
|
Number of Patients With Clinically Significant Laboratory Findings
Time Frame: Month 1, 2, 3, 6, 9, 15 and 30
|
Number of patients with clinically significant laboratory findings, laboratory measurements as an assessment of the tolerability
|
Month 1, 2, 3, 6, 9, 15 and 30
|
|
GAD65AB Titer Measured to Evaluate the Tolerability (Main Study Period)
Time Frame: 6 months
|
GAD65AB titer (GADA) change from baseline.
GAD65AB = Antibodies to GAD with molecular mass 65000
|
6 months
|
|
GAD65AB Titer Measured to Evaluate the Tolerability (Main Study Period)
Time Frame: 15 months
|
GAD65AB titer (GADA) change from baseline.
GAD65AB = Antibodies to GAD with molecular mass 65000
|
15 months
|
|
GAD65AB Titer Measured to Evaluate the Tolerability (Main Study Period)
Time Frame: 30 months
|
GAD65AB titer (GADA) change from baseline.
GAD65AB = Antibodies to GAD with molecular mass 65000
|
30 months
|
|
Number of Patients With an Infection Reported as Adverse Event Related to Study Treatment
Time Frame: Month 1, 2, 3, 6, 9, 15 and 30
|
Number of patients with an infection reported as Adverse Event related to study treatment (GAD-Alum and/or Etanercept),as an assessment of the tolerability
|
Month 1, 2, 3, 6, 9, 15 and 30
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
C-peptide: Area Under the Curve (AUC 0-120 Min) During an MMTT, Change From Baseline
Time Frame: Baseline and 6 months at 0, 30, 60, 90 and 120 minutes post-dose
|
Weighted mean C-peptide: (AUC mean 0-120 min) during an MMTT, change from baseline to 6 months.
MMTT=Mixed Meal Tolerance Test
|
Baseline and 6 months at 0, 30, 60, 90 and 120 minutes post-dose
|
|
C-peptide: Area Under the Curve (AUC 0-120 Min) During an MMTT, Change From Baseline
Time Frame: Baseline and 15 months at 0, 30, 60, 90 and 120 minutes post-dose
|
Weighted mean C-peptide: (AUC mean 0-120 min) during an MMTT, change from baseline to 15 months
|
Baseline and 15 months at 0, 30, 60, 90 and 120 minutes post-dose
|
|
C-peptide: Area Under the Curve (AUC 0-120 Min) During an MMTT, Change From Baseline
Time Frame: Baseline and 30 months at 0, 30, 60, 90 and 120 minutes post-dose
|
Weighted mean C-peptide: (AUC mean 0-120 min) during an MMTT, change from baseline to 30 months
|
Baseline and 30 months at 0, 30, 60, 90 and 120 minutes post-dose
|
|
Number of Patients With a Stimulated Maximum C-peptide Level Above 0.2 Nmol/L
Time Frame: 6 months
|
Number of patients with a stimulated maximum C-peptide level above 0.2 nmol/L at 6 months
|
6 months
|
|
Number of Patients With a Stimulated Maximum C-peptide Level Above 0.2 Nmol/L
Time Frame: 15 months
|
Number of patients with a stimulated maximum C-peptide level above 0.2 nmol/L at 15 months
|
15 months
|
|
Number of Patients With a Stimulated Maximum C-peptide Level Above 0.2 Nmol/L
Time Frame: 30 months
|
Number of patients with a stimulated maximum C-peptide level above 0.2 nmol/L at 30 months
|
30 months
|
|
Hemoglobin A1c (HbA1c), Change From Baseline
Time Frame: Baseline and 6 months
|
Hemoglobin A1c (HbA1c), change from baseline to 6 months
|
Baseline and 6 months
|
|
Hemoglobin A1c (HbA1c), Change From Baseline
Time Frame: Baseline and 15 months
|
Hemoglobin A1c (HbA1c), change from baseline to 15 months
|
Baseline and 15 months
|
|
Hemoglobin A1c (HbA1c), Change From Baseline
Time Frame: Baseline and 30 months
|
Hemoglobin A1c (HbA1c), change from baseline to 30 months
|
Baseline and 30 months
|
|
Exogenous Insulin Dose Per kg Body Weight and 24 Hours, Change From Baseline
Time Frame: Baseline and 6 months
|
Exogenous 24-hour insulin dose per kg body weight and 24 hours average, change from baseline
|
Baseline and 6 months
|
|
Exogenous Insulin Dose Per kg Body Weight and 24 Hours, Change From Baseline
Time Frame: Baseline and 15 months
|
Exogenous 24-hour insulin dose per kg body weight and 24 hours average, change from baseline
|
Baseline and 15 months
|
|
Exogenous Insulin Dose Per kg Body Weight and 24 Hours, Change From Baseline
Time Frame: Baseline and 30 months
|
Exogenous 24-hour insulin dose per kg body weight and 24 hours average, change from baseline
|
Baseline and 30 months
|
|
C-peptide: Stimulated, 90 Minute Value, Change From Baseline
Time Frame: Baseline and 6 months
|
C-peptide: Stimulated, 90 minute value, change from baseline to 6 months
|
Baseline and 6 months
|
|
C-peptide: Stimulated, 90 Minute Value, Change From Baseline
Time Frame: Baseline and 15 months
|
C-peptide: Stimulated, 90 minute value, change from baseline to 15 months
|
Baseline and 15 months
|
|
C-peptide: Stimulated, 90 Minute Value, Change From Baseline
Time Frame: Baseline and 30 months
|
C-peptide: Stimulated, 90 minute value, change from baseline to 30 months
|
Baseline and 30 months
|
|
C-peptide Fasting Concentration, Change From Baseline
Time Frame: Baseline and 6 months
|
C-peptide: Fasting concentration, change from baseline to 6 months
|
Baseline and 6 months
|
|
C-peptide Fasting Concentration, Change From Baseline
Time Frame: Baseline and 15 months
|
C-peptide: Fasting, concentration, change from baseline to 15 months
|
Baseline and 15 months
|
|
C-peptide Fasting Concentration, Change From Baseline
Time Frame: Baseline and 30 months
|
C-peptide: Fasting, concentration, change from baseline to 30 months
|
Baseline and 30 months
|
|
Spontaneous IL-17a Secretion
Time Frame: Baseline, 6 months, 9 months, 15 months and 30 months
|
Spontaneous IL-17a secretion at baseline, 6 months, 9 months, 15 months and 30 months
|
Baseline, 6 months, 9 months, 15 months and 30 months
|
|
GAD65-induced IL-4 Secretion
Time Frame: Baseline, 6 months, 9 months, 15 months, 30 months
|
GAD65-induced IL-4 secretion at baseline, 6 months, 9 months, 15 months, 30 months
|
Baseline, 6 months, 9 months, 15 months, 30 months
|
|
GAD65-induced IL-13 Secretion
Time Frame: Baseline, 6 months, 9 months, 15 months, 30 months
|
GAD65-induced IL-13 secretion at baseline, 6 months, 9 months, 15 months, 30 months
|
Baseline, 6 months, 9 months, 15 months, 30 months
|
|
GAD65-induced IFN-gamma Secretion
Time Frame: Baseline, 6 months, 9 months, 15 months, 30 months
|
GAD65-induced IFN-gamma secretion at baseline, 6 months, 9 months, 15 months, 30 months
|
Baseline, 6 months, 9 months, 15 months, 30 months
|
|
GAD65-induced TNF-alpha Secretion
Time Frame: Baseline, 6 months, 9 months, 15 months, 30 months
|
GAD65-induced TNF-alpha secretion at baseline, 6 months, 9 months, 15 months, 30 months
|
Baseline, 6 months, 9 months, 15 months, 30 months
|
|
GAD65-induced GM-CSF Secretion
Time Frame: Baseline, 6 months, 9 months, 15 months, 30 months
|
GAD65-induced GM-CSF secretion baseline, 6 months, 9 months, 15 months, 30 months
|
Baseline, 6 months, 9 months, 15 months, 30 months
|
|
GAD65-induced MIP-1b Secretion
Time Frame: Baseline, 6 months, 9 months, 15 months, 30 months
|
GAD65-induced MIP-1b secretion at baseline, 6 months, 9 months, 15 months, 30 months
|
Baseline, 6 months, 9 months, 15 months, 30 months
|
|
GAD65-induced MCP-1 Secretion
Time Frame: Baseline, 6 months, 9 months, 15 months, 30 months
|
GAD65-induced MCP-1 secretion at baseline, 6 months, 9 months, 15 months, 30 months
|
Baseline, 6 months, 9 months, 15 months, 30 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gastrointestinal Agents
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Etanercept
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
Other Study ID Numbers
- EDCR IIa
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.